Chronic obstructive pulmonary disease(COPD). Other chronic obstructive pulmonary disease
Conditions
Interventions
Intervention 1: Intervention group: Supplement training group: Subjects in this group will take 1800 mg of N-acetylcysteine supplement (3 times a day and one 600 mg tablet per meal). The combined trai
Sponsors
The University of Mazandaran
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with chronic obstructive pulmonary disease who have been confirmed by a specialist doctor. Patients who have not received any antibiotics, glucocorticoids and theophylline drugs in the 2 weeks before entering the study Patients who have signed the informed consent form for voluntary participation in the study.
Exclusion criteria
Exclusion criteria: Pulmonary interstitial fibrosis Tuberculosis Bronchial pneumonia Lung cancer diabetes Functional liver diseases Cardiovascular diseases Neurological diseases Severe brain disease mental illnesses Cognitive impairment disease Functional kidney diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibrinogen. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples, spirometry, questionnaire.;Interleukin-1. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Interleukin-6. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Interleukin-8. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;TNF-a. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;C-reactive protein. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Nitric oxide. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Xanthine. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Superoxide dismutase. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Glutathione peroxidase. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of blood samples.;Malondialdehyde. Timepoint: 24 hours before the start of the study and 48 hours after the last day of the study (12 weeks later). Method of measurement: Collection of bl | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza Ebrahimi Samarin
University of Mazandaran
Outcome results
None listed